Tax withholding trims Standard BioTools (LAB) CFO share stake

Rhea-AI Filing Summary

STANDARD BIOTOOLS INC. Chief Financial Officer Hanjoon Alex Kim reported a tax-related share disposition. On the vesting of restricted stock units, the company withheld 12,740 shares of common stock at $1.15 per share to cover tax obligations. After this withholding, Kim directly owns 2,407,346 common shares, which includes 5,000 shares acquired on November 28, 2025 under the employee stock purchase plan.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Kim Hanjoon Alex

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	12,740	$1.15	$15K

Holdings After Transaction: Common Stock — 2,407,346 shares (Direct)

Footnotes (1)

1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units granted to the reporting person on May 20, 2024 and March 21, 2025, which grants were originally reported on Form 4s filed with the U.S. Securities and Exchange Commission on May 21, 2024 and March 24, 2025, respectively. Includes 5,000 shares of common stock acquired by the reporting person on November 28, 2025 under the Issuer's Employee Stock Purchase Plan.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kim Hanjoon Alex

(Last) (First) (Middle)

C/O STANDARD BIOTOOLS INC.

50 MILK STREET, 10TH FLOOR

(Street)

BOSTON MA 02109

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
STANDARD BIOTOOLS INC. [ LAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/23/2026		F		12,740(1)	D	$1.15	2,407,346(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units granted to the reporting person on May 20, 2024 and March 21, 2025, which grants were originally reported on Form 4s filed with the U.S. Securities and Exchange Commission on May 21, 2024 and March 24, 2025, respectively.

2. Includes 5,000 shares of common stock acquired by the reporting person on November 28, 2025 under the Issuer's Employee Stock Purchase Plan.

	/s/ Hanjoon Alex Kim by Tomone Tanaka, Attorney-in-Fact	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did STANDARD BIOTOOLS (LAB) report for its CFO?

STANDARD BIOTOOLS reported a tax-related share withholding for its CFO. The company withheld 12,740 common shares to satisfy taxes due on vesting restricted stock units, rather than an open-market sale by the executive.

How many STANDARD BIOTOOLS (LAB) shares were withheld for the CFO’s taxes?

A total of 12,740 STANDARD BIOTOOLS common shares were withheld. The shares covered tax obligations arising from restricted stock units that vested from grants originally made in May 2024 and March 2025.

At what price were the withheld STANDARD BIOTOOLS (LAB) shares valued?

The withheld shares were valued at $1.15 per STANDARD BIOTOOLS share. This price is used in the Form 4 to calculate the value of the 12,740 shares applied to satisfy the CFO’s tax liability on vesting equity awards.

How many STANDARD BIOTOOLS (LAB) shares does the CFO own after this Form 4?

After the tax withholding, the CFO directly owns 2,407,346 STANDARD BIOTOOLS common shares. This total includes 5,000 shares previously acquired through the company’s Employee Stock Purchase Plan on November 28, 2025.

Was the STANDARD BIOTOOLS (LAB) CFO’s Form 4 transaction an open-market sale?

No, the transaction was not an open-market sale. The 12,740 shares were withheld by the company to satisfy tax obligations on vesting restricted stock units, a common administrative disposition coded as a tax-withholding transaction.